JPWO2023274352A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023274352A5 JPWO2023274352A5 JP2023579541A JP2023579541A JPWO2023274352A5 JP WO2023274352 A5 JPWO2023274352 A5 JP WO2023274352A5 JP 2023579541 A JP2023579541 A JP 2023579541A JP 2023579541 A JP2023579541 A JP 2023579541A JP WO2023274352 A5 JPWO2023274352 A5 JP WO2023274352A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- optionally
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/104201 | 2021-07-02 | ||
| CN2021104201 | 2021-07-02 | ||
| PCT/CN2022/102692 WO2023274352A1 (en) | 2021-07-02 | 2022-06-30 | Depletion of activated hepatic stellate cells (hscs) and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024524301A JP2024524301A (ja) | 2024-07-05 |
| JPWO2023274352A5 true JPWO2023274352A5 (https=) | 2025-07-07 |
| JP2024524301A5 JP2024524301A5 (https=) | 2025-07-07 |
Family
ID=84691485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579541A Pending JP2024524301A (ja) | 2021-07-02 | 2022-06-30 | 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240254239A1 (https=) |
| EP (1) | EP4363443A4 (https=) |
| JP (1) | JP2024524301A (https=) |
| KR (1) | KR20240070496A (https=) |
| CN (2) | CN117980328A (https=) |
| AU (1) | AU2022304943A1 (https=) |
| CA (1) | CA3222788A1 (https=) |
| IL (1) | IL309804A (https=) |
| MX (1) | MX2024000057A (https=) |
| TW (1) | TW202317632A (https=) |
| WO (1) | WO2023274352A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230130372A1 (en) | 2019-12-17 | 2023-04-27 | The Board Of Regents Of The University Of Texas System | Novel ddr1 antibodies and uses thereof |
| CN116492463B (zh) * | 2023-03-31 | 2023-11-17 | 珠海市人民医院 | Cd155分子在肝纤维化领域中的应用 |
| WO2025026353A1 (en) * | 2023-08-01 | 2025-02-06 | Laekna Therapeutics Shanghai Co., Ltd. | Anti-acvr2b antibodies and uses thereof |
| CN119930817B (zh) * | 2024-12-24 | 2025-12-02 | 国科大杭州高等研究院 | Tigit全人源抗体及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2011265460B2 (en) * | 2003-01-09 | 2014-07-17 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2012261721A1 (en) * | 2006-03-17 | 2013-01-10 | Gilead Sciences, Inc. | Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists |
| CA2827170A1 (en) * | 2011-02-11 | 2012-08-16 | David M. Hilbert | Monovalent and multivalent multispecific complexes and uses thereof |
| CN104628866B (zh) * | 2015-01-21 | 2018-03-27 | 中国药科大学 | 一种靶向vegfr2的抗体融合蛋白的制备及其用途 |
| CN104592395B (zh) * | 2015-01-27 | 2017-11-14 | 中国药科大学 | Vegfr2单链抗体与mica融合蛋白的制备方法及用途 |
| CN115925933A (zh) * | 2015-12-28 | 2023-04-07 | 依奈特制药公司 | NKp46结合蛋白的可变区 |
| CN110088132B (zh) * | 2016-08-17 | 2020-10-27 | 康姆普根有限公司 | 抗tigit抗体，抗pvrig抗体及其组合 |
| CN111836831A (zh) * | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药 |
| GB201809700D0 (en) * | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| CN114126663A (zh) * | 2019-05-16 | 2022-03-01 | 沙塔克实验室有限公司 | Nk细胞定向的嵌合蛋白 |
-
2022
- 2022-06-30 EP EP22832164.2A patent/EP4363443A4/en active Pending
- 2022-06-30 KR KR1020247000140A patent/KR20240070496A/ko active Pending
- 2022-06-30 AU AU2022304943A patent/AU2022304943A1/en active Pending
- 2022-06-30 JP JP2023579541A patent/JP2024524301A/ja active Pending
- 2022-06-30 CA CA3222788A patent/CA3222788A1/en active Pending
- 2022-06-30 US US18/574,243 patent/US20240254239A1/en active Pending
- 2022-06-30 MX MX2024000057A patent/MX2024000057A/es unknown
- 2022-06-30 IL IL309804A patent/IL309804A/en unknown
- 2022-06-30 TW TW111124547A patent/TW202317632A/zh unknown
- 2022-06-30 WO PCT/CN2022/102692 patent/WO2023274352A1/en not_active Ceased
- 2022-06-30 CN CN202280057249.9A patent/CN117980328A/zh active Pending
- 2022-06-30 CN CN202411176778.8A patent/CN119039440A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| TWI830151B (zh) | 抗GPRC5DxBCMAxCD3三特異性抗體及其用途 | |
| JP7132232B2 (ja) | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 | |
| US20240150464A1 (en) | Materials and methods for modulating t cell mediated immunity | |
| US20180072808A1 (en) | Humanized anti-ox40 antibodies and uses thereof | |
| JP2015533853A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP7170331B2 (ja) | 固形及び血液癌の治療のための併用療法 | |
| CN111417653A (zh) | Cd47抗原结合分子 | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2020508655A5 (https=) | ||
| AU2016226060A1 (en) | CD20 binding molecules and uses thereof | |
| CN108348589A (zh) | 治疗性cd47抗体 | |
| JP2018524326A (ja) | 多重特異的ｎｋエンゲイジャータンパク質 | |
| JP2018522541A5 (https=) | ||
| JPWO2019129221A5 (https=) | ||
| JP2018528776A5 (https=) | ||
| JP2023524238A (ja) | 治療用ＳＩＲＰα抗体 | |
| JP2021505637A (ja) | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 | |
| CN114901364A (zh) | 用于治疗实体癌和血液癌的组合疗法 | |
| CN119213023A (zh) | Ilt3和cd3结合剂以及其使用方法 | |
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| JP2016529213A5 (https=) | ||
| WO2023147331A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen |